Showing results (61-70 of 863) with videos related to
Sort By:
Pageof 87
Blood Reviews|April 3, 2021
Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keysFlora Peyvandi, Isabella Garagiola, Pier Mannuccio MannucciBlood|June 26, 2020
How I treat gastrointestinal bleeding in congenital and acquired von Willebrand diseaseEugenia Biguzzi, Simona Maria Siboni, Flora PeyvandiSeminars in Thrombosis and Hemostasis|October 20, 2015
Assessment of clotting factor concentrates--pivotal studies and long-term requirementsH Marijke van den Berg, Flora PeyvandiInternal and Emergency Medicine|July 29, 2023
Hemophilia patients: are they naturally anticoagulated?Armando Tripodi, Pier Mannuccio Mannucci, Flora PeyvandiJournal of Thrombosis and Haemostasis : JTH|January 26, 2021
Von Willebrand disease type 2N: An updateOmid Seidizadeh, Flora Peyvandi, Pier Mannuccio MannucciThrombosis and Haemostasis|March 23, 2018
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban StudiesAlok A Khorana, Jeffrey I WeitzBritish Journal of Pharmacology|February 16, 2005
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinShannon M Bates, Jeffrey I WeitzAnnals of Internal Medicine|November 1, 2021
In pregnant women with suspected VTE and low/intermediate or unlikely pretest probability, D-dimer rules out VTE at 3 moNoel C Chan, Jeffrey I WeitzCurrent Drug Targets. Cardiovascular & Haematological Disorders|December 20, 2003
An update on new anticoagulantsLori-Ann Linkins, Jeffrey I WeitzNature Reviews. Cardiology|March 14, 2012
Anticoagulation therapy. Dabigatran and risk of myocardial infarctionJohn W Eikelboom, Jeffrey I WeitzPageof 87